Altium Capital Management’s Keros Therapeutics KROS Stock Holding History

Altium Capital Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-175,000	Closed	-$2.77M	–	49
2024 Q4	$2.77M	Buy	175,000 +106,000	+154%	+$5.51M	0.79%	40
2024 Q3	$4.01M	Buy	+69,000	New	+$3.41M	1.18%	31
2022 Q4	–	Sell	-88,000	Closed	-$3.31M	–	116
2022 Q3	$3.31M	Hold	88,000	–	–	1.21%	35
2022 Q2	$2.43M	Sell	88,000 -38,000	-30%	-$1.67M	0.97%	41
2022 Q1	$6.85M	Buy	126,000 +10,000	+9%	+$513K	2.29%	7
2021 Q4	$6.79M	Sell	116,000 -10,000	-8%	-$499K	1.87%	10
2021 Q3	$4.99M	Buy	+126,000	New	+$4.48M	1.31%	31

Other funds holding KROS

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Altium Capital Management's KROS Position: Q1 2025 in Review

Altium Capital Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 175,000 shares — an estimated $2.77M sold.

Altium Capital Management first reported a position in KROS in Q3 2021 and held it in 7 quarters. The position peaked at $6.85M in Q1 2022. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Altium Capital Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
Altium Capital Management sold 175,000 Keros Therapeutics shares in Q1 2025, an estimated $2.77M.
Altium Capital Management first reported a position in Keros Therapeutics in Q3 2021 and held it in 7 quarters.
Altium Capital Management's Keros Therapeutics position peaked at $6.85M in Q1 2022.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.